Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for brolucizumab for treating wet age-related macular degeneration

  1. Brolucizumab for treating diabetic macular oedema (TA820)

    Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    31 August 2022
    View recommendations

    Sections for TA820

  2. Brolucizumab for treating wet age-related macular degeneration (TA672)

    Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Published
    3 February 2021
    View recommendations

    Sections for TA672

  3. Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]

    Awaiting development Reference number: GID-TA10879 Expected publication date:  11 November 2026

    Technology appraisal guidance
    Awaiting development